JP2010522540A5 - - Google Patents

Download PDF

Info

Publication number
JP2010522540A5
JP2010522540A5 JP2009554098A JP2009554098A JP2010522540A5 JP 2010522540 A5 JP2010522540 A5 JP 2010522540A5 JP 2009554098 A JP2009554098 A JP 2009554098A JP 2009554098 A JP2009554098 A JP 2009554098A JP 2010522540 A5 JP2010522540 A5 JP 2010522540A5
Authority
JP
Japan
Prior art keywords
polypeptide
rsv
protein
chimeric
chimeric rsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009554098A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010522540A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2008/001286 external-priority patent/WO2008114149A2/en
Publication of JP2010522540A publication Critical patent/JP2010522540A/ja
Publication of JP2010522540A5 publication Critical patent/JP2010522540A5/ja
Pending legal-status Critical Current

Links

JP2009554098A 2007-03-21 2008-03-20 キメラ抗原 Pending JP2010522540A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89620107P 2007-03-21 2007-03-21
PCT/IB2008/001286 WO2008114149A2 (en) 2007-03-21 2008-03-20 Chimeric antigens

Publications (2)

Publication Number Publication Date
JP2010522540A JP2010522540A (ja) 2010-07-08
JP2010522540A5 true JP2010522540A5 (OSRAM) 2011-05-12

Family

ID=39766560

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009554098A Pending JP2010522540A (ja) 2007-03-21 2008-03-20 キメラ抗原

Country Status (5)

Country Link
US (1) US20100203071A1 (OSRAM)
EP (1) EP2181121A4 (OSRAM)
JP (1) JP2010522540A (OSRAM)
CA (1) CA2684578A1 (OSRAM)
WO (1) WO2008114149A2 (OSRAM)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160000902A1 (en) * 2003-07-11 2016-01-07 Novavax, Inc. Combination vaccine for respiratory syncytial virus and influenza
CA2632630C (en) 2005-12-13 2016-12-06 President And Fellows Of Harvard College Scaffolds for cell transplantation
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
EP4206231A1 (en) 2007-12-24 2023-07-05 ID Biomedical Corporation of Quebec Recombinant rsv antigens
US10328133B2 (en) 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
SG10201500161XA (en) * 2008-12-09 2015-03-30 Novavax Inc Modified rsv f proteins and methods of their use
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
WO2010149743A2 (en) * 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine
ES2583257T3 (es) * 2009-06-24 2016-09-20 Glaxosmithkline Biologicals S.A. Antígenos recombinantes del VSR
ES2563730T3 (es) 2009-07-15 2016-03-16 Glaxosmithkline Biologicals S.A. Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
KR101425405B1 (ko) * 2009-07-17 2014-08-01 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물
JP5926180B2 (ja) * 2009-07-31 2016-05-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 寛容原性療法のための細胞のプログラミングの方法
AU2010279492B2 (en) * 2009-08-04 2015-04-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of The Health And Human Services, Centers For Disease Control And Prevention Anti-RSV immunogens and methods of immunization
JP5890407B2 (ja) 2010-07-07 2016-03-22 アーティフィシャル セル テクノロジーズ インコーポレイテッド 呼吸器合胞体ウイルス抗原組成物および方法
ES2773858T3 (es) 2010-10-06 2020-07-15 Harvard College Hidrogeles formadores de poros inyectables para terapias celulares basadas en materiales
EP2668282A2 (en) * 2011-01-28 2013-12-04 MedImmune, LLC Expression of soluble viral fusion glycoproteins in mammalian cells
JP2014518620A (ja) * 2011-04-26 2014-08-07 モレキュラー エクスプレス，インコーポレイテッド リポソーム製剤
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP2701745B1 (en) 2011-04-28 2018-07-11 President and Fellows of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
SI2707385T1 (en) 2011-05-13 2018-01-31 Glaxosmithkline Biologicals Sa Pregnant RSV F antigens
AU2012261848B2 (en) 2011-06-03 2017-06-15 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
ES2395677B1 (es) * 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
EP2752199A4 (en) 2011-08-29 2015-04-29 Univ Tokushima RSV MUCOSA VACCINE
WO2013049342A1 (en) * 2011-09-30 2013-04-04 Novavax, Inc. Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
CA2870182A1 (en) * 2012-04-10 2013-10-17 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
CN104244929B (zh) 2012-04-16 2017-04-05 哈佛学院董事会 用于调节免疫反应的介孔二氧化硅组合物
EA201891945A3 (ru) * 2012-08-01 2019-05-31 Бавариан Нордик А/С Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv)
ES2767324T3 (es) * 2012-08-01 2020-06-17 Bavarian Nordic As Vacuna de virus vaccinia modificado de Ankara (MVA) recombinante para el virus sincicial respiratorio (VRS)
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
SG11201506197TA (en) * 2013-02-11 2015-09-29 Novavax Inc Combination vaccine for respiratory syncytial virus and influenza
US20160193322A1 (en) 2013-08-05 2016-07-07 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
MX384992B (es) 2014-06-13 2025-03-14 Glaxosmithkline Biologicals Sa Combinaciones inmunógenas.
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
CN114099793A (zh) 2015-04-10 2022-03-01 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
JP6670374B2 (ja) 2015-09-03 2020-03-18 ノババックス，インコーポレイテッド 改善された安定性および免疫原性を有するワクチン組成物
KR102136678B1 (ko) 2015-12-23 2020-07-22 화이자 인코포레이티드 Rsv f 단백질 돌연변이체
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
CA3030427A1 (en) 2016-07-13 2018-01-18 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
JP7274214B2 (ja) 2016-08-02 2023-05-16 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫応答を調節するための生体材料
KR102561368B1 (ko) 2016-08-03 2023-08-01 론자 워커스빌 아이엔씨. 실질적으로 코아굴로겐이 없는 리물루스 아메보사이트 라이세이트를 이용한 내독소 검출방법
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
EP3552021B1 (en) 2017-01-11 2022-10-26 Lonza Walkersville, Inc. Coagulogen-free clarified limulus amebocyte lysate
US12083228B2 (en) 2017-07-24 2024-09-10 Novavax, Inc. Methods and compositions for treating respiratory disease
EP3697919A1 (en) 2017-10-16 2020-08-26 GlaxoSmithKline Biologicals SA Adenoviral vectors with two expression cassettes encoding rsv antigenic proteins or fragments thereof
CA3084358A1 (en) 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa Enhanced promoter
BR112020007413A2 (pt) 2017-10-16 2020-12-08 Glaxosmithkline Biologicals S.A. Vetores adenovirais com dois cassetes de expressão
US11905313B2 (en) 2017-11-28 2024-02-20 The United States of America, as represented by the Secretary, Department of Health and Human Services. Recombinant RSV G proteins and their use
WO2019183063A1 (en) 2018-03-19 2019-09-26 Novavax, Inc. Multivalent influenza nanoparticle vaccines
MX2020013553A (es) 2018-06-12 2021-02-26 Glaxosmithkline Biologicals Sa Polinucleotidos y polipeptidos de adenovirus.
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
KR102725189B1 (ko) 2018-11-01 2024-10-31 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
AU2020227545B2 (en) 2019-02-28 2023-10-19 Km Biologics Co., Ltd. RSV F/G chimeric vaccine
CN114993784B (zh) * 2022-05-27 2025-07-29 重庆医科大学 一种乙肝病毒颗粒裂解液及其制备与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1015595B1 (en) * 1997-09-19 2005-01-26 Wyeth Holdings Corporation Peptides derived from the attachment (g) protein of respiratory syncytial virus

Similar Documents

Publication Publication Date Title
JP2010522540A5 (OSRAM)
EP3319633B1 (en) Vaccine against rsv
HRP20161353T1 (hr) Rekombinantni rsv antigeni
JP2011528222A5 (OSRAM)
JP2012530761A5 (OSRAM)
JP2018515088A5 (OSRAM)
JP2008530245A5 (OSRAM)
JP2012530504A5 (OSRAM)
CA2790380A1 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
WO2020234300A1 (en) A subunit vaccine for treatment or prevention of a respiratory tract infection
HRP20140109T1 (hr) Novi imunoadjuvantni spojevi na bazi flagelina i njihova upotreba
JP2013517783A5 (OSRAM)
JP2010500399A5 (OSRAM)
JP2013515055A5 (OSRAM)
TWI455721B (zh) 癌疫苗組合物
JP2015504052A5 (OSRAM)
CN109734800B (zh) 一种裂谷热病毒人源单克隆抗体及其应用
KR102047072B1 (ko) 메르스 코로나바이러스 핵단백질의 전장 단백질 유전자 및 이를 포함하는 메르스 코로나바이러스 감염 예방용 백신 조성물
SI2797950T1 (en) Fusion protein against cancer
IL285716B (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2009520758A5 (OSRAM)
JP2004538320A5 (OSRAM)
ES2551699T3 (es) Composiciones, procedimientos y kits
CN118891059A (zh) 嵌合多肽